Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unknown Primary Neoplasm Metastasis”

129 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 129 results

Testing effectiveness (Phase 2)Study completedNCT03391973
What this trial is testing

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

Who this might be right for
Carcinoma of Unknown Primary
AHS Cancer Control Alberta 33
Testing effectiveness (Phase 2)Study completedNCT00003657
What this trial is testing

High-dose ICE With Amifostine

Who this might be right for
Bladder CancerBrain and Central Nervous System TumorsCarcinoma of Unknown Primary+8 more
Dana-Farber Cancer Institute 24
Testing effectiveness (Phase 2)Study completedNCT00193622
What this trial is testing

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Who this might be right for
Neoplasms, Unknown Primary
SCRI Development Innovations, LLC 50
Testing effectiveness (Phase 2)Study completedNCT05024968
What this trial is testing

Sintilimab in Cancer of Unknown Primary

Who this might be right for
Cancer of Unknown Primary Site
M.D. Anderson Cancer Center 10
Not applicableLooking for participantsNCT04504604
What this trial is testing

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Who this might be right for
Rare CancersCholangiocarcinomaCancer of Unknown Primary Site
TargetCancer Foundation 400
Not applicableWithdrawnNCT04985357
What this trial is testing

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Who this might be right for
Stage III Breast CancerStage IV Breast CancerStage III Lung Cancer+35 more
Travera Inc
Testing effectiveness (Phase 2)Looking for participantsNCT04273061
What this trial is testing

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Who this might be right for
Breast CancerLung CancerGastrointestinal Cancer+6 more
British Columbia Cancer Agency 50
Not applicableUnknownNCT04952103
What this trial is testing

Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China

Who this might be right for
Cancer of Unknown Primary Site
Fudan University 200
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Ended earlyNCT03628079
What this trial is testing

A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

Who this might be right for
Cancer of the Gastrointestinal TractCancer of Unknown Origin
Repos Pharma 11
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Large-scale testing (Phase 3)Study completedNCT00193596
What this trial is testing

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Who this might be right for
Neoplasms, Unknown Primary
SCRI Development Innovations, LLC 198
Early research (Phase 1)Study completedNCT00003867
What this trial is testing

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Who this might be right for
Cancer
Montefiore Medical Center 30
Large-scale testing (Phase 3)Study completedNCT04189107
What this trial is testing

Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS

Who this might be right for
AnalgesiaSurgeryCancer of Head and Neck+4 more
Rigshospitalet, Denmark 18
Testing effectiveness (Phase 2)WithdrawnNCT00119314
What this trial is testing

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Who this might be right for
Carcinoma of Unknown Primary
University of Medicine and Dentistry of New Jersey
Testing effectiveness (Phase 2)UnknownNCT05241132
What this trial is testing

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Who this might be right for
Cancer of Unknown PrimaryBone Cancer MetastaticTislelizumab+3 more
Wei Xu 27
Testing effectiveness (Phase 2)UnknownNCT02764216
What this trial is testing

Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary

Who this might be right for
Head-and-neck CancerCarcinoma of Unknown Primary
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 48
Not applicableStudy completedNCT05461430
What this trial is testing

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Who this might be right for
Pleural Effusion, MalignantAscites, MalignantCarcinoma+29 more
Travera Inc 72
Testing effectiveness (Phase 2)Looking for participantsNCT06636734
What this trial is testing

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Who this might be right for
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown PrimaryMetastatic Head and Neck Squamous Cell Carcinoma+19 more
Emory University
Not applicableStudy completedNCT01202786
What this trial is testing

Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

Who this might be right for
Neoplasms, Unknown Primary
Teva Branded Pharmaceutical Products R&D, Inc. 60
Next Page
28